A method of inhibiting kidney cell apoptosis in a subject in need thereof, comprising administering an effective amount of a composition consisting of (a) cyclo histidine-proline (CHP) or its pharmaceutically acceptable salt as an active ingredient and (b) one or more additives selected from the group consisting of sodium starch glycolate, crospovidone, croscarmellose sodium, alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium, chitosan, guar gum, low-substituted hydroxypropylcellulose, magnesium aluminum silicate, polacrilin potassium, starch, gelatinized starch, microcrystalline cellulose, lactose, povidone, colloidal silicon dioxide, calcium hydrogen phosphate, mannitol, sugar, arabic gum, pregelatinized starch, corn starch, powdered cellulose, hydroxypropylcellulose, opadry, sodium starch glycolate, carnauba lead, synthetic aluminum silicate, stearic acid, magnesium stearate, aluminum stearate, calcium stearate, white sugar, dextrose, sorbitol, and talc, to the subject,
- wherein the kidney cell apoptosis is caused by administration of a drug;
- and
- wherein the subject suffers from one or more selected from the group consisting of chronic pyelonephritis, nephrotic syndrome, nephrogenic diabetes insipidus and hyperuricemia.